The invention relates to the field of healthcare, namely, to the treatment of socially significant diseases, such as complications of diabetes mellitus, atherosclerosis, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases including Alzheimer's and Parkinson's diseases, cataract, age-related diseases, etc. The essence of the invention is the use of sulfasalazine (international non-proprietary name; synonyms: Salazosulfapyridine, Azopyrine, Asulfidine, Salazopyridin, Salazopyrin, Salazosulfapyridine, Salicylazosulfapyridin, Salisulf, Sulfasalazyn, Sulphasalazine) of the general formula I as an inhibitor of the formation of advanced glycation end-products:

##STR00001##

The invention relates to the field of healthcare, namely, to the treatment of socially significant diseases, such as complications of diabetes mellitus, atherosclerosis, rheumatoid arthritis, osteoarthritis, neurodegenerative diseases including Alzheimer's and Parkinson's diseases, cataract, age-related diseases, etc. The essence of the invention is the use of sulfasalazine (international non-proprietary name; synonyms: Salazosulfapyridine, Azopyrine, Asulfidine, Salazopyridin, Salazopyrin, Salazosulfapyridine, Salicylazosulfapyridin, Salisulf, Sulfasalazyn, Sulphasalazine) of the general formula I as an inhibitor of the formation of advanced glycation end-products:

##STR00001##

Systems and methods for delivering active ingredients, such as pharmaceutically active ingredients, to substrates are described herein. The active ingredients are delivered as fluids to a fluid-dispensing device for the creation of one or more drops for deposition onto substrates such as for the creation of microdoses. The invention further includes microdoses made by such processes.

Systems and methods for delivering active ingredients, such as pharmaceutically active ingredients, to substrates are described herein. The active ingredients are delivered as fluids to a fluid-dispensing device for the creation of one or more drops for deposition onto substrates such as for the creation of microdoses. The invention further includes microdoses made by such processes.

The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1

##STR00001## Where X.sup.−═CH.sub.3COO.sup.− or HOOCCH.sub.2CH.sub.2COO.sup.−, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.

The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1

##STR00001## Where X.sup.−═CH.sub.3COO.sup.− or HOOCCH.sub.2CH.sub.2COO.sup.−, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: ##STR00001##
or a pharmaceutically acceptable salt or prodrug thereof, wherein A.sub.1-A.sub.3, B.sub.1-B.sub.3, D.sub.1-D.sub.4 and R.sub.1-R.sub.2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

The disclosure relates to substituted fused heteroaromatic tricyclic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: ##STR00001##
or a pharmaceutically acceptable salt or prodrug thereof, wherein A.sub.1-A.sub.3, B.sub.1-B.sub.3, D.sub.1-D.sub.4 and R.sub.1-R.sub.2 are defined herein. Compounds having Formula I are ATM kinase inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.